News Center

Home page

Peak Report

News reports

Announcement on the consistency evaluation of subsidiary drugs through generic drugs.

Release time:

2021-05-20

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Pro 2020-002

Zhejiang Jianfeng Group Co., Ltd.

Announcement

on Compliance Evaluation of Subsidiary Drugs Passing Generic Drugs The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Company " ), a controlling subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "" Jianfeng Pharmaceutical "), received the" Drug Supplementary Application Approval "for paroxetine hydrochloride tablets approved and issued by the State Drug Administration (batch number: 2020B02472 ), Jianfeng Pharmaceutical Paroxetine Hydrochloride Tablets have passed the consistency evaluation of generic drug quality and curative effect (hereinafter referred to as" generic drug consistency evaluation "). The relevant information is hereby announced as follows:

1. Drug Basic Information

Drug Name: Paroxetine Hydrochloride Tablets

Dosage Form: Tablet

Specification: 20mg (calculated by C ₁₉H ₂₀FNO ₃)

Registration Classification: Chemical

Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.

Acceptance No.: CYHB1950106

Batch No.: 2020B02472

Approval Conclusion: according to the provisions of the the People's Republic of China Drug Administration Law, the Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices (Guo Fa (2015 ) 44 ) and the Announcement on Matters Related to the Evaluation of Quality and Efficacy Consistency of Generic Drugs (2017 100 ), after examination, this product has passed the evaluation of quality and efficacy consistency of generic drugs.

OTHER CONDITIONS RELATED TO 2. MEDICINE

(I) FUNCTION INDICATIONS: This product is used to treat depression, obsessive compulsive disorder, panic disorder with or without square terrors, social phobia/ social anxiety disorder. After the curative effect is satisfied, continue to take this product can prevent the recurrence of depression, panic disorder and obsessive-compulsive disorder.

(II) The National Drug Administration received the application for consistency evaluation of the drug in January of 2019 1 .

(III) As of the date of disclosure of this report, the drug research and development investment of about 1289 yuan (unaudited).

(IV) Included in the National Medical Insurance and Basic Drug List: Paroxetine Hydrochloride Tablets have been included in the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug List (2019 Edition ) and classified as Class A; It has been listed in the National Essential Drug List (2018 Edition ) .

(V) the market situation of similar drugs: domestic enterprises that have passed the consistency evaluation of this drug are: Zhejiang Huahai Pharmaceutical Co., Ltd., Beijing Fuyuan Pharmaceutical Co., Ltd., and Sino-US Tianjin SmithKline Pharmaceutical Co., Ltd. In 2018 , the sales of paroxetine hydrochloride tablets in domestic hospitals were about 3.78 .8 billion yuan (data from the database of drug intelligence network). In 2018 , Jianfeng Pharmaceutical achieved a cumulative sales of paroxetine hydrochloride tablets of about 9739.49 yuan.

3. Risk Alert

According to relevant national policies, drug varieties that pass the consistency evaluation will receive greater support in the fields of medical insurance payment and medical institution procurement. If there are more than 3 manufacturers of the same variety of drugs that pass the consistency evaluation of generic drugs, the varieties that do not pass the consistency evaluation of generic drugs will no longer be selected in the centralized procurement of drugs. The Paroxetine Hydrochloride Tablets of Jianfeng Pharmaceuticals has passed the quality and efficacy consistency evaluation of generic drugs, which is conducive to expanding the market share of the drug and enhancing its market competitiveness. As drug sales are affected by national policies, market environment and other factors, there is greater uncertainty. Investors are advised to pay attention to investment risks.

is hereby announced.

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors

March 11, 2020

More information

The company organized "charity one day donation"

On the morning of October 22, in the lobby on the first floor of Jianfeng Building, all cadres and employees of the group headquarters and subordinate enterprises working in Jianfeng Building participated in the 2021 "Charity Day Donation" activity to offer their love to Jinhua charity. In the next few days, the company's subordinate enterprises also organized "charity one-day donation" activities one after another.

2021

11-01

The company organizes new employee induction training

"Growth is more important than success. I hope everyone can become the backbone and pillars of the peak as soon as possible." On September 2, Yu Jianhong, general manager of the group company, put forward ardent hopes in the face of new employees. On the 2nd and 3rd, the group company organized induction training for new employees recruited in the past year. The group company chairman Jiang Xiaomeng, general manager Yu Jianhong and other leaders and relevant department heads gave lectures to them.

2021

09-13

Daye Peak: Typical Regional Industrial Green Development

On August 23, Huangshi Radio and Television Station broadcast the special program of "Strengthening Overall Planning and Promoting Energy Saving and Emission Reduction in Industrial Field". Daye Jianfeng Cement Company, as a typical enterprise with outstanding achievements in establishing green factories and energy saving and emission reduction in Huangshi area, appeared in the program.

2021

09-01

Yunnan Peak Helps Border Epidemic Prevention and Control

On August 22, Yunnan Peak Cement Company, through the Red Cross Society of Pu'er City and the Epidemic Prevention Headquarters of Pu'er City, donated vacuum insulation pots with a total value of 800000 yuan to the four border counties for the prevention and control of the new coronary pneumonia epidemic in the border area, and supported the prevention and control of the epidemic at the border with practical actions.

2021

09-01

Group Party Committee to Learn "July 1" Important Speech

On August 13, the party committee of the group company held a special meeting to collectively study General Secretary Xi Jinping's important speech at the celebration meeting of the 100 anniversary of the founding of the Communist Party of China, convey the requirements of the party committee at a higher level, and make arrangements for organizing party members of the company to study the "July 1" speech.

2021

08-23

Spike Ranked 2020 China's Top 100 Cement Clinker Production Capacity

Recently, the company received the "2020 China Cement Clinker Production Capacity Top 100" plaque issued by China Cement Network. The ranking of China's top 100 cement clinker production capacity is organized and evaluated by China Cement Network, an authoritative information platform for the domestic cement industry. It is released according to the actual clinker production capacity of each cement enterprise at the end of last year. The company has been ranked in the top 100 list for many consecutive years.

2021

08-23

< 1...8 9 10...61 > 跳转到页